- Home
- FTFT vs NXTC Comparison
FTFT vs NXTC Comparison
Compare FTFT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- NXTC
- Stock Information
- Founded
- FTFT N/A
- NXTC 2015
- Country
- FTFT United States
- NXTC United States
- Employees
- FTFT 40
- NXTC N/A
- Industry
- FTFT Business Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- NXTC Health Care
- Exchange
- FTFT Nasdaq
- NXTC Nasdaq
- Market Cap
- FTFT 11.0M
- NXTC 13.0M
- IPO Year
- FTFT N/A
- NXTC 2019
- Fundamental
- Price
- FTFT $3.18
- NXTC $5.40
- Analyst Decision
- FTFT
- NXTC Strong Buy
- Analyst Count
- FTFT 0
- NXTC 2
- Target Price
- FTFT N/A
- NXTC $25.50
- AVG Volume (30 Days)
- FTFT 281.4K
- NXTC 16.9K
- Earning Date
- FTFT 08-19-2025
- NXTC 11-06-2025
- Dividend Yield
- FTFT N/A
- NXTC N/A
- EPS Growth
- FTFT N/A
- NXTC N/A
- EPS
- FTFT N/A
- NXTC N/A
- Revenue
- FTFT $2,368,206.00
- NXTC N/A
- Revenue This Year
- FTFT N/A
- NXTC N/A
- Revenue Next Year
- FTFT N/A
- NXTC N/A
- P/E Ratio
- FTFT N/A
- NXTC N/A
- Revenue Growth
- FTFT N/A
- NXTC N/A
- 52 Week Low
- FTFT $1.01
- NXTC $2.69
- 52 Week High
- FTFT $5.70
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- FTFT 74.35
- NXTC 57.83
- Support Level
- FTFT $2.00
- NXTC $4.77
- Resistance Level
- FTFT $3.10
- NXTC $5.15
- Average True Range (ATR)
- FTFT 0.36
- NXTC 0.22
- MACD
- FTFT 0.09
- NXTC 0.05
- Stochastic Oscillator
- FTFT 63.16
- NXTC 86.90
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.